US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
FR2758331B1
(fr)
*
|
1997-01-14 |
1999-03-05 |
Univ Bourgogne |
Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
WO1999012553A1
(fr)
*
|
1997-09-08 |
1999-03-18 |
Idec Pharmaceuticals Corporation |
Procedes de production d'anticorps humains dans des souris scid a l'aide de cellules dendritiques
|
PT2180007E
(pt)
*
|
1998-04-20 |
2013-11-25 |
Roche Glycart Ag |
Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
US6900299B1
(en)
*
|
1999-03-11 |
2005-05-31 |
University Of South Florida |
Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
|
AR030019A1
(es)
*
|
1999-05-18 |
2003-08-13 |
Smithkline Beecham Corp |
Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
|
GB9918788D0
(en)
*
|
1999-08-10 |
1999-10-13 |
Leuven K U Res & Dev |
Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
PT1265928E
(pt)
*
|
2000-01-27 |
2010-09-30 |
Medimmune Llc |
Anticorpos neutralizantes com afinidade ultra-elevada
|
AU3480001A
(en)
|
2000-02-02 |
2001-08-14 |
Government of the United States as represented by the Secretary of the Department of Commerce, The |
CD40 ligand adjuvant for respiratory syncytial virus
|
US7700735B2
(en)
*
|
2000-03-01 |
2010-04-20 |
Medimmune, Llc |
High potency recombinant antibodies and method for producing them
|
CA2409689A1
(fr)
*
|
2000-05-03 |
2001-11-08 |
Medimmune, Inc. |
Polytherapie de maladies respiratoires utilisant des anticorps
|
US6818216B2
(en)
*
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
CA2430039C
(fr)
*
|
2000-11-28 |
2014-01-28 |
Medimmune, Inc. |
Procedes d'administration / de dosage d'anticorps anti-rsv destines a la prevention et au traitement
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
US20040096451A1
(en)
*
|
2002-07-25 |
2004-05-20 |
Young James F. |
Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
|
JP2005503999A
(ja)
|
2001-01-31 |
2005-02-10 |
アイデック ファーマスーティカルズ コーポレイション |
腫瘍性疾患の治療のためのcd23拮抗剤の使用
|
US20050031583A1
(en)
*
|
2001-03-23 |
2005-02-10 |
Iqbal Grewal |
Uses of opg to modulate immune responses
|
CA2442801A1
(fr)
*
|
2001-04-02 |
2002-10-10 |
Idec Pharmaceutical Corporation |
Anticorps recombinants co-exprimes avec gntiii
|
WO2002102303A2
(fr)
|
2001-05-01 |
2002-12-27 |
Medimmune, Inc. |
Cristaux et structure de synagis fab
|
CN1526011A
(zh)
*
|
2001-07-10 |
2004-09-01 |
IDECҩ�﹫˾ |
抑制凋亡过程及改善细胞性能
|
CA2455365C
(fr)
|
2001-08-03 |
2014-07-29 |
Glycart Biotechnology Ag |
Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
|
US7306919B1
(en)
*
|
2001-10-31 |
2007-12-11 |
Thornthwaite Jerry T |
Antigen-antibody cancer recognition system
|
JP2005522996A
(ja)
*
|
2001-11-02 |
2005-08-04 |
セントカー・インコーポレーテツド |
Rsvタンパク質、抗体、組成物、方法および使用
|
AU2003215116A1
(en)
*
|
2002-02-11 |
2003-09-04 |
Alexion Pharmaceuticals, Inc. |
Human antibodies for therapy against vaccinia or smallpox
|
JP2005517401A
(ja)
*
|
2002-02-11 |
2005-06-16 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
免疫欠損非ヒト哺乳動物宿主におけるヒト抗体の産生
|
AU2003220805A1
(en)
*
|
2002-03-28 |
2003-10-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Antiopoietin-related growth factor
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
*
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
CA2490747A1
(fr)
*
|
2002-06-21 |
2003-12-31 |
Centocor, Inc. |
Procede de generation d'anticorps monoclonaux
|
KR100604038B1
(ko)
*
|
2002-08-02 |
2006-07-24 |
주식회사유한양행 |
항체 중쇄 발현벡터
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
WO2004066933A2
(fr)
*
|
2003-01-27 |
2004-08-12 |
Biogen Idec Ma Inc. |
Compositions et methodes permettant de traiter le cancer au moyen de igsf9 et de liv-1
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
KR101106441B1
(ko)
|
2003-03-19 |
2012-01-18 |
바이오겐 아이덱 엠에이 인코포레이티드 |
노고 수용체 결합 단백질
|
JPWO2004087761A1
(ja)
*
|
2003-03-31 |
2006-07-27 |
麒麟麦酒株式会社 |
ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7070786B2
(en)
*
|
2003-06-06 |
2006-07-04 |
Centocor, Inc. |
RSV proteins, antibodies, compositions, methods and uses
|
KR20120098932A
(ko)
|
2003-06-27 |
2012-09-05 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
WO2005037999A2
(fr)
*
|
2003-10-14 |
2005-04-28 |
Biogen Idec Ma Inc. |
Traitement anticancereux a base d'anticorps diriges contre lrrc15
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
AU2003304600A1
(en)
*
|
2003-11-14 |
2005-06-29 |
Avanir Pharmaceuticals |
Neutralizing human antibodies to anthrax toxin generated by recall technology
|
US20060246079A1
(en)
|
2003-11-14 |
2006-11-02 |
Morrow Phillip R |
Neutralizing human antibodies to anthrax toxin
|
WO2005081749A2
(fr)
*
|
2004-01-23 |
2005-09-09 |
Avanir Pharmaceuticals, Inc. |
Anticorps humains neutralisants diriges contre la toxine du charbon
|
WO2005060520A2
(fr)
*
|
2003-11-25 |
2005-07-07 |
Dana-Farber Cancer Institute, Inc. |
Anticorps diriges contre sras-cov et methodes d'utilisation de ceux-ci
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
EP2474317A1
(fr)
*
|
2004-06-24 |
2012-07-11 |
Biogen Idec MA Inc. |
Traitement des maladies impliquant la démyélinisation
|
EP1789070B1
(fr)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Influence du taj sur les fonctions neuronales
|
US20060063187A1
(en)
*
|
2004-09-15 |
2006-03-23 |
Hotamisligil Gokhan S |
Modulation of XBP-1 activity for treatment of metabolic disorders
|
EP1807111A4
(fr)
*
|
2004-10-08 |
2009-05-27 |
Abbott Biotech Ltd |
Infection a virus respiratoire syncytial (rsv)
|
CA2585891A1
(fr)
*
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methodes de prevention et de traitement des infections a rsv et des etats pathologiques associes
|
BRPI0606398A
(pt)
|
2005-01-05 |
2008-03-11 |
Biogen Idec Inc |
moléculas de criptoligação
|
EP2343320B1
(fr)
|
2005-03-25 |
2017-10-25 |
GITR, Inc. |
Anticorps contre gitr et leur utilisations
|
JP5372500B2
(ja)
*
|
2005-06-17 |
2013-12-18 |
トレラクス リクイデーティング トラスト |
Ilt3結合分子およびその使用
|
EP1904104B1
(fr)
|
2005-07-08 |
2013-09-11 |
Biogen Idec MA Inc. |
Anticorps anti-sp35 et leurs utilisations
|
US20100304358A1
(en)
*
|
2005-08-15 |
2010-12-02 |
Shuming Nie |
Methods of identifying biological targets and instrumentation to identify biological targets
|
JP2009517340A
(ja)
|
2005-11-04 |
2009-04-30 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法
|
WO2007062037A2
(fr)
*
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono Sa |
Compositions et methodes de production de molecules hybrides de fixant a des antigenes, et leurs utilisations
|
EP2543384A3
(fr)
|
2005-12-02 |
2013-04-10 |
Biogen Idec MA Inc. |
Traitement des conditions impliquant la démyélinisation
|
EP2540820B1
(fr)
*
|
2005-12-09 |
2018-01-10 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Moyens et procédés permettant d'influencer la stabilité de cellules produisant des anticorps
|
NZ569816A
(en)
*
|
2005-12-16 |
2011-10-28 |
Ribovax Biotechnologies Sa |
Methods for obtaining immortalized antibody secreting cells
|
BRPI0707276B1
(pt)
|
2006-01-27 |
2021-08-31 |
Biogen Ma Inc |
Polipeptídeo de fusão antagonista de receptor nogo
|
WO2007101441A1
(fr)
*
|
2006-03-06 |
2007-09-13 |
Symphogen A/S |
Anticorps polyclonal de recombinaison pour le traitement d'infections par le virus respiratoire syncytial
|
TW200813086A
(en)
|
2006-05-11 |
2008-03-16 |
Hoffmann La Roche |
Immunereconstituted mouse
|
CA2655903A1
(fr)
*
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Molecules se liant a l'ilt3 et leurs utilisations
|
WO2008079322A1
(fr)
*
|
2006-12-22 |
2008-07-03 |
Beckman Coulter, Inc. |
Procédés, coffrets et matériels pour diagnostiquer des états de maladie par la mesure d'isoformes ou de proformes de la myéloperoxydase
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
JP2010515456A
(ja)
|
2007-01-09 |
2010-05-13 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Sp35抗体およびその使用
|
EP2134747A2
(fr)
*
|
2007-03-06 |
2009-12-23 |
Symphogen A/S |
Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
EP1997830A1
(fr)
*
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
Molécules à liaison spécifiques RSV et leur moyen de fabrication
|
WO2009009116A2
(fr)
*
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Thérapies combinées utilisant des molécules de liaison au gitr
|
CA2704134A1
(fr)
*
|
2007-09-24 |
2009-04-02 |
Vanderbilt University |
Anticorps monoclonaux au virus respiratoire syncytial et leurs utilisations
|
ES2883176T3
(es)
|
2007-11-08 |
2021-12-07 |
Prec Biologics Inc |
Anticuerpos monoclonales recombinantes y antígenos correspondientes para cánceres de colon y de páncreas
|
WO2009067820A1
(fr)
*
|
2007-11-27 |
2009-06-04 |
The University Of British Columbia |
Compositions et procédés pour la prévention et le traitement de l'arthrite
|
KR100938998B1
(ko)
*
|
2008-01-08 |
2010-01-28 |
(주) 에이프로젠 |
호흡기 신시티움 바이러스에 대한 항체
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
WO2009147248A2
(fr)
|
2008-06-05 |
2009-12-10 |
Ablynx N.V. |
Séquences d'acides aminés dirigées contre des protéines d'enveloppe d'un virus, et polypeptides comprenant ces séquences destinés au traitement de maladies virales
|
WO2010005570A2
(fr)
|
2008-07-09 |
2010-01-14 |
Biogen Idec Ma Inc. |
Compositions comprenant des anticorps anti-lingo ou leurs fragments
|
EP2145621A1
(fr)
|
2008-07-16 |
2010-01-20 |
Stephan Lück |
Prévention de la déshydratation et réduction de pertes glucoformatrices d'acides aminés à l'aide de propane-1,2,3-triol
|
JP5575377B2
(ja)
*
|
2008-07-18 |
2014-08-20 |
シスメックス株式会社 |
抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
JP2012521216A
(ja)
|
2009-03-24 |
2012-09-13 |
テバ バイオファーマスーティカルズ ユーエスエー,インコーポレーテッド |
Lightに対するヒト化抗体およびその使用
|
RU2016103067A
(ru)
|
2009-06-05 |
2018-11-20 |
Аблинкс Нв |
Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
|
RU2585227C2
(ru)
|
2009-07-15 |
2016-05-27 |
Новартис Аг |
Композиции белка f rsv и способы их получения
|
KR101778317B1
(ko)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법
|
WO2011034582A2
(fr)
*
|
2009-09-16 |
2011-03-24 |
Duke University |
Anticorps anti-vih-1
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
WO2011064382A1
(fr)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
|
WO2011119920A2
(fr)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Glycoprotéines du cmv et vecteurs recombinés
|
EP2400298B1
(fr)
*
|
2010-05-28 |
2013-08-14 |
F.Hoffmann-La Roche Ag |
Procédé de culture de lymphocyte simple et production d'anticorps spécifque
|
AR082149A1
(es)
|
2010-07-09 |
2012-11-14 |
Calmune Corp |
Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
|
TW201217527A
(en)
|
2010-07-09 |
2012-05-01 |
Biogen Idec Hemophilia Inc |
Processable single chain molecules and polypeptides made using same
|
EP2422618A1
(fr)
|
2010-08-27 |
2012-02-29 |
Technologie Integrale Ltd. |
Modèle animal pour l'évaluation de l'efficacité d'un vaccin contre le VIH
|
WO2012109238A2
(fr)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
|
EP2699688A1
(fr)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air
|
CA2832109C
(fr)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Glycoproteines de cmv et vecteurs recombinants cmv
|
SI2717898T1
(sl)
|
2011-06-10 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Spojine prokoagulantov in metode za njihovo uporabo
|
WO2013012733A1
(fr)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
WO2013040307A1
(fr)
*
|
2011-09-16 |
2013-03-21 |
Granata, Francesco |
Procédés de fabrication de cellules, de tissus et d'anticorps
|
CN102850454B
(zh)
*
|
2011-09-27 |
2014-06-25 |
上海博沃生物科技有限公司 |
抗呼吸道合胞病毒的人单克隆抗体
|
EP2586461A1
(fr)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Particules virales dérivées d'un virus enveloppé
|
PE20141937A1
(es)
|
2011-11-16 |
2014-12-18 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
|
DK2802606T3
(en)
|
2012-01-10 |
2018-06-25 |
Biogen Ma Inc |
INCREASE TRANSPORT OF THERAPEUTIC MOLECULES OVER THE BLOOD-BRAIN BARRIER
|
WO2013173364A2
(fr)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
|
US20150239956A1
(en)
*
|
2012-06-27 |
2015-08-27 |
Asahi Kasei Medical Co., Ltd. |
High-affinity antibody and method for manufacturing the same
|
EP2679596B1
(fr)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
Variante de la protéine env du VIH-1
|
AU2013344992A1
(en)
*
|
2012-11-13 |
2015-05-14 |
Genentech, Inc. |
Enrichment of antigen-specific plasmablasts
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
CN104981149B
(zh)
|
2013-01-29 |
2022-03-04 |
巴斯夫植物科学有限公司 |
表达ein2的抗真菌植物
|
BR112015017345A2
(pt)
|
2013-01-29 |
2017-11-21 |
Basf Plant Science Co Gmbh |
método para aumentar a resistência aos fungos em uma planta, construção de vetor recombinante, planta transgênica, método para produção de planta transgência, uso de qualquer um dos ácidos nucleicos exógenos, parte que pode ser colhida de uma planta transgênica, produto derivado de uma planta, método para produção de um produto e método para cultivar uma planta resistente a fungos
|
WO2014117988A1
(fr)
|
2013-01-29 |
2014-08-07 |
Basf Plant Science Company Gmbh |
Plantes résistantes aux champignons exprimant hcp7
|
TWI659968B
(zh)
|
2013-03-14 |
2019-05-21 |
再生元醫藥公司 |
針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
|
SG10201707600XA
(en)
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
US9856313B2
(en)
|
2013-03-15 |
2018-01-02 |
Xiamen University |
Epitope of RSV fusion protein and antibody recognizing the same
|
EP2970446A1
(fr)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Constructions d'anticorps pour m2 et cd3 de grippe
|
HUE045859T2
(hu)
|
2013-03-15 |
2020-01-28 |
Amgen Res Munich Gmbh |
N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák
|
WO2014203988A1
(fr)
*
|
2013-06-21 |
2014-12-24 |
アルフレッサファーマ株式会社 |
Dispositif d'immunochromatographie pour détecter le vrs
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
ES2724300T3
(es)
|
2013-09-25 |
2019-09-10 |
Univ Cornell |
Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
|
EP2873423B1
(fr)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines d'enveloppe du vih -1 soluble
|
US10980896B2
(en)
|
2013-10-29 |
2021-04-20 |
President And Fellows Of Harvard College |
Methods and compositions for inhibiting oxidative stress
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
MY186389A
(en)
|
2014-05-13 |
2021-07-22 |
Univ Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
MX2017001401A
(es)
|
2014-07-31 |
2017-08-07 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
|
AU2015295242B2
(en)
|
2014-07-31 |
2020-10-22 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
CA2973266A1
(fr)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de demyelinisation
|
BR112017016688B1
(pt)
|
2015-02-04 |
2024-01-23 |
Basf Plant Science Company Gmbh |
Método para aumentar a resistência fúngica, método para a produção de um produto e método para criar uma planta resistente a fungos
|
EP3069730A3
(fr)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EA201792193A1
(ru)
|
2015-04-17 |
2018-05-31 |
Эмджен Рисерч (Мьюник) Гмбх |
Конструкции биспецифического антитела для cdh3 и cd3
|
US11535665B2
(en)
|
2015-05-13 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated expression of anti-influenza antibodies and methods of use thereof
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
SI3411404T1
(sl)
|
2016-02-03 |
2023-01-31 |
Amgen Research (Munich) Gmbh |
Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
JP6959011B2
(ja)
|
2016-02-03 |
2021-11-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
Bcmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
|
US10626126B2
(en)
*
|
2016-04-08 |
2020-04-21 |
Pulmocide Limited |
Compounds
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
EP3054014A3
(fr)
|
2016-05-10 |
2016-11-23 |
BASF Plant Science Company GmbH |
Utilisation d'un fongicide sur des plantes transgéniques.
|
WO2018075974A2
(fr)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anticorps anti-virus respiratoire syncytial, et leurs procédés de génération et d'utilisation
|
US11479600B2
(en)
|
2016-10-21 |
2022-10-25 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
KR102695416B1
(ko)
*
|
2016-10-21 |
2024-08-13 |
아디맵 엘엘씨 |
항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
PT3589730T
(pt)
|
2017-02-28 |
2024-02-28 |
Univ Pennsylvania |
Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
|
SG11201907611WA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
TWI761453B
(zh)
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
AU2018261951A1
(en)
|
2017-05-05 |
2019-10-31 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
JP7166342B2
(ja)
*
|
2017-11-30 |
2022-11-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
B細胞培養法
|
JP7344206B2
(ja)
|
2017-12-11 |
2023-09-13 |
アムジェン インコーポレイテッド |
二重特異性抗体製品のための連続製造プロセス
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
SG11202100710TA
(en)
|
2018-07-30 |
2021-02-25 |
Amgen Res Munich Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
CN112512581A
(zh)
|
2018-08-03 |
2021-03-16 |
安进研发(慕尼黑)股份有限公司 |
针对cldn18.2和cd3的抗体构建体
|
LT3843757T
(lt)
|
2018-08-27 |
2024-07-10 |
Affimed Gmbh |
Kriokonservuotos nk ląstelės iš anksto pakrautos antikūno konstruktu
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
US20220186200A1
(en)
|
2019-03-11 |
2022-06-16 |
Basf Se |
Amylases and methods for making and using them
|
JP2022537650A
(ja)
|
2019-06-13 |
2022-08-29 |
アムジエン・インコーポレーテツド |
生物製剤の製造における自動化された生物量に基づく灌流制御
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
EP4058485A1
(fr)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Procédé de réduction de la formation d'agrégats dans le traitement en aval de molécules de liaison à l'antigène bispécifiques
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
EP4081554A1
(fr)
|
2019-12-27 |
2022-11-02 |
Affimed GmbH |
Procédé de production de construction d'anticorps bispécifique fcyriii x cd30
|
WO2021150824A1
(fr)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
CA3175275A1
(fr)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Anticorps contre la mucine 17 et leurs utilisations
|
WO2021202463A1
(fr)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anticorps anti-rsv
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
CA3183693A1
(fr)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Administration attenuant des effets indesirables d'une construction d'anticorps bispecifique de liaison a cd33 et cd3
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
EP4240767A1
(fr)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Constructions polypeptidiques se liant à cd3
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
CA3198064A1
(fr)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Domaine de liaison a l'antigene a taux de coupure reduit
|
TW202233679A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究(慕尼黑)公司 |
選擇性地與cldn6和cd3結合的多肽構建體
|
CN116670152A
(zh)
|
2020-12-01 |
2023-08-29 |
宾夕法尼亚州大学信托人 |
具有组织特异性靶向基序的新型组合物和含有其的组合物
|
TW202313681A
(zh)
|
2021-04-02 |
2023-04-01 |
美商安進公司 |
Mageb2結合構建體
|
WO2022232289A1
(fr)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Vecteurs d'adn non viraux exprimant des anticorps thérapeutiques et leurs utilisations
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发(慕尼黑)股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
EP4376958A1
(fr)
|
2021-07-30 |
2024-06-05 |
Affimed GmbH |
Corps duplex
|
WO2023078968A1
(fr)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Liants de cd16a bispécifiques
|
AU2022381918A1
(en)
|
2021-11-03 |
2024-06-13 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023177655A1
(fr)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2024059675A2
(fr)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Composition de stabilisation de molécule bispécifique
|